Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03399604 · ClinicalTrials.gov registry record · Phase 3
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
A Phase 3 study, sponsored by Liquidia Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT03399604 is a Phase 3 study that has completed, run by Liquidia Technologies. The registered enrollment target is 121 participants.
The verdict
NCT03399604, a Phase 3 study, has completed, sponsored by Liquidia Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
Interventions
- DRUG LIQ861 Inhaled Treprostinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2019-11-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03399604
The ClinicalTrials.gov registry entry for NCT03399604 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Liquidia Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LIQ861 Inhaled Treprostinil is the first listed.
NCT03399604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03399604 about?
NCT03399604 is a clinical study titled "Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil". The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
What is the current status of trial NCT03399604?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2018-01-02. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT03399604?
The interventions under investigation include: LIQ861 Inhaled Treprostinil (DRUG).
Who is sponsoring clinical trial NCT03399604?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.